Adhera Therapeutics Inc (ATRX) Financials
Newest figures come from the 10-Q for Q3 FY2023, filed Nov 20, 2023. Each column of the statement tables below links to the filing it was taken from.
This page shows Adhera Therapeutics Inc (ATRX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Shrinking assets are supporting persistent liabilities, while operations have repeatedly depended on financing inflows rather than internally generated cash.
From FY2021 to FY2022, assets fell from$196K to$79K while liabilities remained above$22M , so the balance sheet became even more dominated by obligations despite a lower liability total. The combination of negative equity and a FY2022 current ratio of 0.0035 indicates that reported current assets were negligible relative to amounts due within the current-liability category.
FY2018 operating losses of
Financing cash flow provided
Financial Health Signals
Adhera Therapeutics Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
Adhera Therapeutics Inc earned -$0.83 per diluted share (EPS) in Q3 2023. Against the prior quarter it is down 8200.0%.
Not reported for Q3 2023.
Not reported for Q3 2023.
Not reported for Q3 2023.
Cash & Balance Sheet
Adhera Therapeutics Inc held $32K in cash as of Q3 2023; long-term debt is not reported for that period.
Not reported for Q3 2023.
Not reported for Q3 2023.
Margins & Returns
None of these metrics is reported for Q3 2023.
Capital Allocation
None of these metrics is reported for Q3 2023.
ATRX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-Q | Q3'2210-Q | Q2'2210-Q | Q1'2210-Q | Q4'2110-K |
|---|---|---|---|---|---|---|---|---|
| SG&A Expenses | $43K-80.8% | $296K-34.1% | $353K+35.8% | N/A | $224K-3.3% | $449K+271.1% | $260K | N/A |
| Operating Income | N/A | -$296K+34.1% | -$353K-35.8% | N/A | -$548K-136.0% | -$449K-248.1% | -$260K | N/A |
| Net Income | N/A | $271K+176.0% | N/A | N/A | N/A | $98K | -$74K | N/A |
| EPS (Basic) | -$0.83-45.6% | $0.07+125.9% | -$0.29+43.1% | -$0.02+99.0% | -$0.57+91.1% | -$0.27-237.5% | -$0.51-325.0% | -$2.01 |
| EPS (Diluted) | -$0.83 | -$0.01 | N/A | N/A | -$0.57 | -$0.27 | N/A | N/A |
| Diluted Shares (Avg) | 4M | 99M | N/A | N/A | 3M | 1M | N/A | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, EBITDA, Interest Expense, Income Tax.
ATRX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-Q | Q3'2210-Q | Q2'2210-Q | Q1'2210-Q | Q4'2110-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $44K-82.8% | $82K-91.6% | $104K-38.8% | $79K-59.9% | $256K+69.5% | $976K+2223.8% | $170K+16900.0% | $196K+19500.0% |
| Current Assets | $44K-82.8% | $82K-91.6% | $104K-38.8% | $79K-59.9% | $256K+69.5% | $976K+2223.8% | $170K+16900.0% | $196K+19500.0% |
| Cash & Equivalents | $32K-75.6% | $58K-93.2% | $69K+72.5% | $32K-57.9% | $133K-11.9% | $849K+1921.4% | $40K+3900.0% | $76K+7500.0% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $26.4M+19.5% | $22.9M+9.1% | $23.2M-9.6% | $22.3M-12.0% | $22.1M+8.2% | $21.0M+28.0% | $25.7M+65.5% | $25.3M+71.6% |
| Current Liabilities | $26.4M+19.5% | $22.9M+9.1% | $23.2M-9.6% | $22.3M-12.0% | $22.1M+8.2% | $21.0M+28.0% | $25.7M+65.5% | $25.3M+71.3% |
| Non-Current Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0+100.0% |
| Total Equity | -$26.3M-20.7% | -$22.8M-14.0% | -$23.1M+9.4% | -$22.2M+11.6% | -$21.8M-7.7% | -$20.0M-22.4% | -$25.5M-64.4% | -$25.1M-70.3% |
| Retained Earnings | -$60.0M-8.3% | -$56.4M-5.3% | -$56.7M-6.0% | -$55.8M-5.2% | -$55.4M-8.6% | -$53.6M-14.4% | -$53.5M-16.4% | -$53.0M-18.8% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
ATRX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-Q | Q3'2210-Q | Q2'2210-Q | Q1'2210-Q | Q4'2110-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$29K+95.6% | -$316K+33.3% | -$310K-43.5% | -$59K+80.1% | -$666K-165.3% | -$474K-558.3% | -$216K | -$296K |
| Stock-Based Compensation | $143K-7.1% | N/A | N/A | N/A | $154K | $0 | N/A | N/A |
| Financing Cash Flow | $4K+107.6% | $305K-76.2% | $347K+92.8% | -$42K-119.2% | -$50K-113.8% | $1.3M+1035.4% | $180K | $220K |
| Dividends Paid | $27K+209.2% | $27K-86.8% | $26K-92.8% | N/A | $9K-97.7% | $202K | $364K | N/A |
| Share Buybacks | N/A | N/A | N/A | $0 | $0 | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Investing Cash Flow.
ATRX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$22.2M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Adhera Therapeutics Inc ATRX | FY2022 | N/A | N/A | N/A | $72K | — |
| GB Sciences GBLX | FY2024 | $0 | N/A | N/A | $81K | — |
| U S Stem Cell Inc USRM | FY2022 | $82K | N/A | N/A | $64K | — |
| Syros Pharmaceut SYRS | FY2023 | $9.9M | -$164.6M | N/A | $3.1M | — |
| Aridis Pharmaceuticals Inc ARDS | FY2022 | $3.1M | -$30.4M | N/A | $4K | — |
Where Adhera Therapeutics Inc Ranks
Frequently Asked Questions
What are Adhera Therapeutics Inc's total assets?
Adhera Therapeutics Inc (ATRX) had $79K in total assets as of fiscal year 2022, including both current and long-term assets.
What is Adhera Therapeutics Inc's current ratio?
Adhera Therapeutics Inc (ATRX) had a current ratio of 0.00 as of fiscal year 2022, which is below 1.0, which may suggest potential liquidity concerns.
Why is Adhera Therapeutics Inc's debt-to-equity ratio negative or not reported?
Adhera Therapeutics Inc (ATRX) has negative shareholder equity of -$22.2M as of fiscal year 2022, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.